Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
4
Neutral
6
Bullish
4
Bearish
21
Neutral
6
Bullish
19
Bearish
17
Neutral
0
Bullish
15
Discovery themes featuring this stock
Privi Speciality Chemicals Limited is an integrated Indian manufacturer, supplier and global exporter of aroma and fragrance chemicals operating multiple manufacturing units and two R&D centres, with deep capabilities in pine chemistry, CST/GTO processing and a diversified portfolio of more than 75 products serving leading fragrance houses and FMCG clients worldwide.
The company reported strong results in Q3 and 9M FY26: consolidated revenue grew 24% YoY to Rs.611 crore in Q3 and Rs.1,857 crore for nine months, EBITDA expanded materially (37% Q3, 47% 9M) and margins rose above 25%, driven by operational efficiencies, improved product mix and state incentives, leading to sharp PAT growth versus prior year.
Management is executing a Rs.1,200 crore, three‑phase expansion to add capacity and new speciality product lines—raising total capacity from 48,000 MTPA toward 74,000 MTPA—and targets the 5k:1k vision (Rs.5,000 crore revenue, Rs.1,000 crore EBITDA) within three to four years assuming timely commissioning and market uptake.
The strategic JV PRIGIV with Givaudan is now contributing positively; it posted positive EBITDA in Q3 FY26 and will receive a Rs.50 crore equity infusion plus a Rs.150 crore non‑interest trade advance from Givaudan to deleverage the JV, indicating strong partner support and potential for incremental high‑value speciality molecule revenues.
Privi’s competitive edge combines the world’s largest single CST processing capacity, long‑term CST supply contracts with 70+ paper mills, top sustainability credentials (EcoVadis Platinum, CDP A) and a 116‑member R&D team, positioning the company to benefit from bio‑based demand, regulatory carbon regimes and China+1 sourcing trends.
Chemicals & Petrochemicals
Specialty Chemicals
14,045 Cr
Low Risk
42.9
44.1
0.6
9.9
3,775.70
2,175.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
477.35 | 17,315 Cr | 42.02 | 2.91 | 0.21 | 7.04 | 6.41 | 3.15 | ||
3670.00 | 15,887 Cr | 38.45 | 4.01 | 0.68 | 10.62 | 14.23 | 4.98 | ||
4787.00 | 14,814 Cr | 35.97 | 5.56 | 0.23 | 15.65 | 20.00 | 13.91 | ||
1232.00 | 14,222 Cr | 83.61 | 4.31 | 0.12 | 5.10 | 7.68 | 2.77 | ||
3580.00 | 14,045 Cr | 42.92 | 9.94 | 0.28 | 23.19 | 21.43 | 9.99 | ||
1306.90 | 13,487 Cr | 30.40 | 4.27 | 0.65 | 14.03 | 18.72 | 12.36 | ||
725.00 | 11,556 Cr | 36.35 | 3.70 | 0.34 | 8.89 | 10.37 | 5.63 | ||
| Median: 7 Co. | — | 1306.90 | 14,222 Cr | 38.45 | 4.27 | 0.28 | 10.62 | 14.23 | 5.63 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Privi Speciality Chemicals Ltd (PRIVISCL) is currently trading at 3,580.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Privi Speciality Chemicals Limited is an integrated Indian manufacturer, supplier and global exporter of aroma and fragrance chemicals operating multiple manufacturing units and two R&D centres, with deep capabilities in pine chemistry, CST/GTO processing and a diversified portfolio of more than 75 products serving leading fragrance houses and FMCG clients worldwide. The company reported strong results in Q3 and 9M FY26: consolidated revenue grew 24% YoY to Rs.611 crore in Q3 and Rs.1,857 crore for nine months, EBITDA expanded materially (37% Q3, 47% 9M) and margins rose above 25%, driven by operational efficiencies, improved product mix and state incentives, leading to sharp PAT growth versus prior year. Management is executing a Rs.1,200 crore, three‑phase expansion to add capacity and new speciality product lines—raising total capacity from 48,000 MTPA toward 74,000 MTPA—and targets the 5k:1k vision (Rs.5,000 crore revenue, Rs.1,000 crore EBITDA) within three to four years assuming timely commissioning and market uptake. The strategic JV PRIGIV with Givaudan is now contributing positively; it posted positive EBITDA in Q3 FY26 and will receive a Rs.50 crore equity infusion plus a Rs.150 crore non‑interest trade advance from Givaudan to deleverage the JV, indicating strong partner support and potential for incremental high‑value speciality molecule revenues. Privi’s competitive edge combines the world’s largest single CST processing capacity, long‑term CST supply contracts with 70+ paper mills, top sustainability credentials (EcoVadis Platinum, CDP A) and a 116‑member R&D team, positioning the company to benefit from bio‑based demand, regulatory carbon regimes and China+1 sourcing trends.
Over the past 52 weeks, Privi Speciality Chemicals Ltd has traded between a low of ₹2,175.00 and a high of ₹3,775.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Privi Speciality Chemicals Ltd has a market capitalization of approximately 14,045.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Privi Speciality Chemicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.92 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,045.19 Cr, Privi Speciality Chemicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Privi Speciality Chemicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Privi Speciality Chemicals Ltd is 42.92. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The share price fell sharply due to a large block deal where a promoter entity sold a 9.28% stake in the company, leading to increased selling pressure in the market.
Earnings Call/Transcript
Privi Speciality Chemicals will hold an earnings conference call on Friday, July 31, 2026 at 15:30 IST to discuss operational and financial performance for Q1 ended June 30, 2026.
Earnings Call/Transcript
Privi Speciality Chemicals announced an Earnings Conference Call on Friday, July 31, 2026 at 15:30 IST to discuss operational and financial performance for Q1 ended June 30, 2026. Pre-registration link and dial-in details provided.
Board Meeting
Privi Speciality Chemicals: Board meeting on 2026-07-30 to consider and approve unaudited standalone and consolidated financial results for quarter ended June 30, 2026. Trading window closed from July 01, 2026 and reopens August 03, 2026.
Board Meeting
Privi Speciality Chemicals Ltd: Board meeting scheduled on 30 July 2026 to consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026; trading window closed Jul 1–opens Aug 3.
